Eric Lefkofsky; Philanthropist and Renowned Entrepreneur

Eric Lefkofsky the chief executive of Tempus most recently collaborated with the University of Chicago to utilize the data from the genome sequence and machine familiarization from Tempus. The aim of this was to equip the doctors with customized data that will ultimately aid the doctors to cater to the patients adequately. The treatment is modified for breast cancer patients and the data is provided through molecular analysis and sequencing.

Mr Eric is an astute entrepreneur situated in the US. He has an unwavering commitment to the cause of making cancer extinct. He also holds an executive position in several other successful conglomerates including Uptake Technologies, Echo Global Logistics, Lightbank, InnerWorkings, Groupon, and Mediaocean. Eric Lefkofsky also serves the Steppenwolf Theatre Company as the Chairman of the panel of Trustees. He is also a Trustee of the Lurie Children’s Hospital of Chicago.

Tempus is integral to the collection and analysis of data on up to 1000 cancer patient due to the fact that there is little to no access to information on the people who have suffered under the disease. This is an alarming statistic because breast cancer is one of the widely spread forms of cancer and lack of the data translates to the doctors giving treatment without the aid of patient information. The impact that Tempus makes to this is that this data they collect will be sufficient in enhancing the treatment development project. Click here to know more.

The initiative that has been undertaken by Tempus will propel the creation of one of the broadest clinically based database. Tempus has combined efforts with the Mayo Clinic, University of Michigan and the Rush University Medical Center among others

Eric Lefkofsky founded the Lefkofsky Family Foundation as part of his philanthropic ventures to help bring about dynamic changes to people it assists.

Eric Lefkofsky Using Tempus to Bring Technology into Cancer Treatment

When Elizabeth Lefkofsky, wife of Eric Paul Lefkofsky was diagnosed with cancer a few years ago, it was a critical turning point for the prominent American entrepreneur. The founder and CEO of Tempus embarked on a journey to invest in technology for the research and treatment of cancer. His company has developed an operating system that connects anatomic and molecular data with other clinical data to help doctors create more efficient and personalized ways to cure cancer. Using historical information from patients with cancer from around the country, doctors can now adjust their treatment methods to suit a patient. His company is helping health facilities take cancer treatment to the next level using. So far, Tempus has collaborated with such prominent organizations as Lurie Comprehensive Cancer Center and Rush University Medical Center.

Born on September 2, 1969, Eric Lefkofsky grew up in Southfield, Michigan. He attended Southfield-Lathrup High School before joining the University of Michigan, from which he graduated in 1991. Mr. Lefkofsky then enrolled at University of Michigan Law School for his Juris Doctor. After his graduation in 1993, Lefkofsky and his college friend Brad Keywell bought an apparel company, Brandon Apparel. This was the first of a string of investments that the two entrepreneurs would make together over the following years. You can also visit the site.

Lefkofsky’s interest in the technology industry began in earnest in 1999. Together with Keywell, Lefkofsky founded one of the early internet companies, Starbelly, which specialized in selling promotional products. So successful was the company that the following year, Starbelly was bought by Halo Industries. Later, in 2001, Lefkofsky co-founded InnerWorkings, another technology company that offered print procurement services to midsized companies across the country. The company went on to have a successful IPO in 2006. Lefkofsky and Keywell partnered to found a freight logistics company, Echo Global Logistics, in 2005. In June 2006, the two created MediaBank, which went on to merge with Donovan Data Systems to create Mediaocean in 2012. In 2007, Lefkofsky co-founded, which later changed its name to Groupon is currently the fastest growing company of all time. Lefkofsky has interests in several other companies and is an active supporter of charitable, scientific and educational causes worldwide.

Follow at Twitter:

How Eric Lefkofsky Is Helping Thousands To Save His Wife

Eric Lefkofsky is famous for having founded the Lefkofsky Family Foundation with his wife, which had the purpose of advancing and supporting scientific researches that improve the quality of life of the general public, but there is more to the story this. Eric wasn’t always a philanthropical figure, and it all began after his wife was diagnosed with breast cancer.

Before it all happened, Lefkofsky was a growing personality in the e-commerce business with his $2.2 billion company called Groupon. The brand is globally known and has a remarkable presence in many countries around the globe.

The terrifying reality of his wife becoming a target of cancer has set the couple on a new path that Lefkofsky didn’t image he would follow. He noticed that answers were not rising and that research was moving so slowly that it was painful to expect a fix to the problem. Then, as a businessman who already began a startup in the past, the man decided to do it himself, founding the company called Tempus.

The biggest accomplishment of Tempus was the technology to connect anatomic and molecular data with clinical information from other systems around the country. This achievement makes up for an enormous bubble of real-time information, much like a Google search engine, that allows doctors and specialists to make better decisions with the extensive knowledge they have available to them.

Even though Lefkofsky was already listed among the biggest billionaires in the world, he changed his life-time occupation to understand healthcare and disease treatments, and it all happened because of his wife’s cancer.

Eric is backed up by an entire team of professionals and specialists, including his director, Kevin White. Both are fighting together “to take cancer treatment to the next level using modern technology.”

The advanced system that was developed by Tempus, alongside the constant research that is being formulated and incentivized in the organization, brings many solutions to partnering doctors to treat their patients better. It improved what medicine is capable of doing. Eric at Twitter .

Eric and Liz are continuously supporting philanthropical initiatives related to a better education system, developing research in diseases and quality of life without looking to profit. They also have supported a project called 1871 FEMtech, alongside Google and the Motorola Mobility Foundation, to progress what the human technology can do. for more .

Oncotarget: Potent Source for Oncological Research Data

Sharing the results of scientific research is the key to advancing those studies into the future. Oncotarget is peer-review journal that focuses on oncological research as well as studies related to cancer care and treatment.

In recent months, Oncotarget has seen an increase in it readership. This has occurred primarily because the content in each issue of the journal is constructive, insightful, current, and appropriately peer-reviewed.

The editorial board of Oncotarget includes a Nobel Prize winner, Andrew Schally. Schally has seen his own papers published in Oncotarget. The fact that a Nobel Prize winner seeks to have his work published in this journal speaks volumes about the reputation and quality of content of Oncotarget.

The papers published in Oncotarget were cited over 10,000 times during the course of 2016. This represents approximately a 300 percent increase over citations in 2015. In other words, continues to glean even greater notice in the oncology research, cancer treatment, and medical communities.

Oncotarget is described as a multidisciplinary journal published on Impact Journals. It is available to researchers, medical professionals, journalists, and the public-at-large free of charge. The publication maintains that life without disease is the ultimate mission of Oncotarget.

Oncotarget has garnered attention for its focus on publishing articles and papers about oncological and associated research that currently is in progress. Publication during research allows for an important exchange of information and data that enhances the subject studies as well as others that are impacted by these particular research results.

Oncotarget was founded by Mikhail V. Blagosklonny and Andrei V. Gudkov of the Roswell Park Cancer Institute. These two cancer research specialists remain as the co-editors-in-chief of the publication. In addition to their leadership of the publication, the editorial board consists of a couple dozen other experts in the field. This includes professionals from revered institutions like Harvard Medical School, Columbia University, Stanford University School of Medicine, and John Hopkins University School of Medicine.

Follow Oncotarget on Twitter.